- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06117397
A Text Messaging Intervention to Reduce Perinatal Depression Risk (PTMI)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Massachusetts
-
Worcester, Massachusetts, United States, 01655
- UMass Chan Medical School
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- English speaking
- "At risk" as determined by an Edinburgh Postnatal Depression Scale score of at least 9, or an average score >3 on the 6-item Medical Outcomes Social Support Survey or history of depression in pregnancy or postpartum depression
- At least age 16
- Are willing and able to provide informed consent
- Are willing to use a smart phone to receive texts
Exclusion Criteria:
- In a major depressive episode
- Planning on terminating pregnancy
- Have panic disorder or substance use disorder
- Currently in behavioral health care treatment
- Blind individuals
- Permanently living in an institutional setting
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Text4Moms
Texts will include video links that reinforce information relevant to Interpersonal Psychotherapy (IPT).
|
A text messaging intervention that includes enhanced content such as tailoring, video links and a chat function
|
|
No Intervention: Educational Control
The control condition will be limited to texts related to pregnancy, nutrition and sleep.
We will avoid elements that have behavioral therapeutic effects.
Although this condition is meant to constitute time and attention control, we will include material on recognizing depression and links to ways to attain depression treatment and suicide hotline information.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
General Self Efficacy Scale
Time Frame: Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
10 item measure of self efficacy.
Items are scored 1-4, with scores ranging between 10 and 40.
A higher score indicates more self-efficacy.
Will be administered three times (for pre-pilot administered at baseline, 2 weeks, and 4 weeks; for pilot administered at baseline, 4 weeks, and 8 weeks).
|
Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
|
Patient engagement with text messages
Time Frame: 0-8 weeks
|
Percentage of participants opening >80% of text messages and clicking on >30% of links to enhanced content.
|
0-8 weeks
|
|
Patient engagement with chat
Time Frame: 0-8 weeks
|
Percentage of participants engaging with chat and endorsing 4 out of 5 on its utility.
|
0-8 weeks
|
|
Edinburgh Prenatal Depression Scale
Time Frame: Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
10-item continuous measure of depression.
Self-report that will be administered by computer.
Will be administered three times (for pre-pilot administered at screening, 2 weeks, and 4 weeks; for pilot administered at screening, 4 weeks, and 8 weeks).
Items are scored 0-3, with a maximum score of 30.
Higher scores show increased severity.
|
Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
|
System Usability Scale
Time Frame: Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
10 items rated on a 1-5 scale, with scores ranging from 0-100, with a higher score indicating greater acceptability.
Will be administered one times (for pre-pilot administered at 4 weeks; for pilot administered at 8 weeks).
|
Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Diagnosis of a major depressive episode
Time Frame: Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
Diagnosis of a major depressive episode using the PHQ-9, the Major Depressive Disorder module of the full PHQ.
Will be administered three times (for pre-pilot administered at screening, 2 weeks, and 4 weeks; for pilot administered at screening, 4 weeks, and 8 weeks).
|
Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
|
User Engagement Scale
Time Frame: Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
12 items rated on a 1-5 scale, with scores ranging from 10-50, with higher scores indicating greater acceptability, with an average score of 80.3.
Will be administered one time (for pre-pilot administered at 4 weeks; for pilot administered at 8 weeks).
|
Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
|
Perlin Mastery Scale
Time Frame: Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
7 items scaled on a 1-4 scale, with scores ranging from 7-28.
Low scores indicate low mastery.
Will be administered one time at baseline.
|
Week 4 for pre-pilot and week 8 for pilot, adjusted for baseline
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: Kimberly Yonkers, MD, UMass Chan Medical School
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 00000462
- R34MH130934-03 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
We welcome any interest in using or modifying the intervention materials developed under this project, which will be aided by our use of the Computerized Intervention Authoring System (CIAS) platform. Our overall plan will include presentations at national scientific meetings as well as publication of results, via reputable peer-reviewed journals and the National Library of Medicine/PubMed Central. We will deposit this dataset with the National Database for Clinical Trials Related to Mental Illness. We will indicate in publications and presentations where and how to access these data. Study materials and information regarding access to intervention content will be made available via the Open Science Framework (OSF).
Individuals who would like our data can also complete a "data analysis requisition form" that describes their specific hypotheses with mock-ups of tables. All data will be de-identified before sharing. We will make the data available under a data sharing agreement.
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Major Depressive Episode
-
Assistance Publique - Hôpitaux de ParisNot yet recruitingSignature Response to Light Therapy in Unipolar and Bipolar Major Depressive Episode (MDE) (SoLuRep)Major Depressive EpisodeFrance
-
University Hospital, MontpellierRecruitingMajor Depressive EpisodeFrance
-
Medical University of ViennaUnknownMajor Depressive EpisodeAustria
-
The University of New South WalesWesley MissionUnknown
-
Northside Clinic, AustraliaWesley MissionCompletedMajor Depressive EpisodeAustralia
-
Jiangsu Province Nanjing Brain HospitalRecruiting
-
Jiangsu Province Nanjing Brain HospitalCompletedMajor Depressive EpisodeChina
-
Assistance Publique - Hôpitaux de ParisRecruiting
-
Alto NeuroscienceRecruitingBipolar Disorder I or II With a Major Depressive EpisodeUnited States
-
Neumora Therapeutics, Inc.CompletedMajor Depressive Episode Associated With Bipolar II DisorderUnited States
Clinical Trials on Text Messaging Intervention
-
Washington University School of MedicineCompletedObesity | Overweight | Severe Mental DisorderUnited States
-
University of WashingtonJohn L. Locke Jr. Charitable TrustTerminatedMyocardial Infarction | Percutaneous Coronary Intervention | Coronary Artery Bypass Surgery | Chronic Stable Angina | Left Ventricular Assist Device | Heart Transplant | Chronic Stable Heart Failure | Heart Valve Repair or ReplacementUnited States
-
University of MichiganNational Institute on Aging (NIA)Not yet recruitingAging | Physical Inactivity | Behavior Change | Cognitive AbilityUnited States
-
University of PennsylvaniaBenefits Data TrustCompletedSocial Determinants of HealthUnited States
-
Jonsson Comprehensive Cancer CenterWithdrawnSurvivors of Childhood CancerUnited States
-
Georgetown UniversityCompleted
-
The University of Hong KongNot yet recruitingIntervention | ControlHong Kong
-
Duke UniversityNational Institutes of Health (NIH)Withdrawn
-
Yale UniversityCompletedBreast Cancer | Adherence, Medication | Side EffectUnited States
-
Columbia UniversitySociety of Family PlanningCompleted